The COGCOV Study in ICU Patients (COGCOV)
Long-term Cognitive Impairment in ICU Patients, Admitted for COVID-19 Pneumonia: a Single Centre, Prospective Cohort Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Elly Vandermeulen, PhD
- Phone Number: +3289325407
- Email: elly.vandermeulen@zol.be
Study Locations
-
-
-
Genk, Belgium, 3600
- Ziekenhuis Oost-Limburg
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Admitted to the intensive care unit of Ziekenhuis Oost-Limburg
- Being hospitalized between March 2020 and May 2020, and therefore being admitted 6 months prior to the study
- The reason of hospitalization was COVID-19 disease
Exclusion Criteria:
- No willingness to participate, and therefore not having signed the informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: COVID-19 patients
Neurocognitive impairment in COVID-19 patients
|
6 months after admission to the intensive care unit of Ziekenhuis Oost-Limburg, the patients will be tested on cognitive impairment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neurocognitive impairment measured by RBANS
Time Frame: 6 months after admission at the intensive care unit
|
the Repeatable Battery for the Assessment of Neuropsychological Statusis (RBANS) is a neuropsychological test that provides information about 5 domains of cognition (1) immediate and (2) delayed memory, (3) attention, (4) visuospatial construction and (5) language) and provides a total score.
It is a test that takes about 30 minutes and consists of twelve tests.
These are: (1) List Learning, (2) Story Memory, (3) Figure Copy, (4) Line Orientation, (5) Picture Naming, (6) Semantic Fluency, (7) Digit Span, (8) Coding, (9) List Recall, (10) List Recognition, (11) Story Recall and (12) Figure Recall.
According to the RBANS manual, the possible values for the RBANS scores at the item, domain, and scale level are 0 to 89, 40 to 154, and 40 to 160
|
6 months after admission at the intensive care unit
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neurocognitive impairment measured by TMT
Time Frame: 6 months after admission at the intensive care unit
|
Trail Making Test (TMT) is a test of executive functioning, visual search speed, scanning, speed of processing and mental flexibility.
The total score is the time in seconds spent to complete each part.
|
6 months after admission at the intensive care unit
|
|
Neurocognitive impairment by the short IQCODE
Time Frame: 6 months after admission at the intensive care unit
|
The short IQCODE is a 16 question long questionnaire that assesses cognitive impairment in elderly patients.
An informant is required to rate a patient's cognitive changes over a 10 year time period.
Each question is scored from 1 (much improved over time) to 5 (much worse).
|
6 months after admission at the intensive care unit
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Dieter Mesotten, MD, Ziekenhuis Oost-Limburg
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Neurocognitive Disorders
- Cognition Disorders
- COVID-19
- Cognitive Dysfunction
Other Study ID Numbers
Other Study ID Numbers
- COGCOV
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.